Active clinical trials for "Diabetes Mellitus"

In recent years, due to the frequent occurrence of kidney disease and diabetes, the number of patients entering maintenance hemodialysis is increasing. With the economic development and dialysis quality improving year by year, the survival time of uremic patients is significantly prolonged, and the hazards of various complications are increasingly prominent. Cognitive impairment is a common complication of maintenance hemodialysis patients, and its specific mechanism is not yet clear. Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) are independent risk factors for cognitive impairment. The prevalence of cognitive impairment is higher in patients with type 2 diabetes and advanced chronic kidney disease, especially in patients with diabetes and end-stage renal disease (ESKD). T2DM and ESKD independently increase the risk of cerebrovascular disease and cognitive impairment. However, the relationship between diabetes mellitus and cognitive function in maintenance hemodialysis patients is unclear. However, compared with the general population, patients with type 2 diabetes mellitus (T2DM) and patients with advanced chronic kidney disease (CKD) had more severe brain atrophy, and the severity of white matter lesions on brain MRI increased. To sum up, the study of cognitive dysfunction is very important in maintenance hemodialysis patients with diabetes. It is urgent for us to explore the changes of cognitive impairment and brain magnetic resonance in maintenance hemodialysis patients with diabetes, so as to help detect brain cell damage and improve the survival rate and quality of life in the early stage of the disease.

There is a close association between overweight, abdominal type, and type 2 diabetes mellitus (T2DM).The scientific literature of recent years shows the existing relationship between weight loss, of 15% or more of body weight, and the positive effect on body composition parameters as well as on glycemic profiles. Specifically, here the investigator focuses on very low carbohydrate ketogenic diets (VLCKDs) as a nutritional strategy for managing excess weight and improving diabetes. Current knowledge is changing the face of T2DM, showing that an effective, appropriate and early intervention can lead to a remission of diabetes involving a partial recovery of insulin secretion as well as its action. Nevertheless, the daily life of the diabetic patient followed in an office can be less linear than that of a patient participating in a study protocol, with planned follow-up visits and close supervision. What about the impact of VLCKD, observed in clinical studies, in patients with T2DM in real-life? In order to answer this question, we would like to analyze here a series of patient files with T2DM and overweight, followed in a private practice, specializing in diabetology, who have adhered to a VLCKD, by a commercial method (PnK® Method), in order to improve their glycemic control.

The goal of this randomized control trial is to test the efficacy and safety of the sterile wound care liquid dressing in patients with diabetes foot ulcer in different stages. The main question it aims to answer are: Whether the sterile wound care liquid dressing have better efficacy and safety than blank control in treatment of diabetes foot ulcer in infection progressive stage？ Whether the sterile wound care liquid dressing have better efficacy and safety than blank control in treatment of diabetes foot ulcer in necrosis stable stage？ Whether the sterile wound care liquid dressing have better efficacy and safety than blank control in treatment of chronic wound in granulation growth stage？ Participants will be assigned with a 1:1 ratio into intervention group and control group. Participants of intervention group will receive sterile wound care liquid dressing in addition with clinical optimal treatment plan. Participants of control group will only receive clinical optimal treatment plan.

In this multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with degludec/insulin aspart (IDegAsp) once daily plus insulin aspart (IAsp) twice daily after 16weeks of treatment in patients with type 2 diabetes mellitus. This trial will enable primary assessment of the clinically relevant endpoint of a change in HbA1c.

A randomized clinical trial (RCT) will be carried out to compare the reuse or not of needles in patients with type 2 diabetes (T2DM) that use insulin. Two groups will be studied: a group that will not reuse the needles and a group that will reuse the needles five times. The aim of this study is to evaluate related outcomes such as bruises, infection, lipodystrophy, pain and glycemic control, whether or not to reuse insulin delivery needles in patients with T2DM who use insulin.

Women with type 2 diabetes (n=150) experiencing ≥1 storage lower urinary tract symptoms and poor sleep health will be recruited from the outpatient departments or wards/units of the selected hospitals/clinics. Our study aims to examine the effects of conservative management incorporating urologic health promotion and sleep health promotion on relieving storage lower urinary tract symptoms and poor sleep, and on improving urologic health self-management behaviors and health-related quality of life. Women who agree to participate will be randomly assigned into the intervention group A, intervention group B, or comparison group. The intervention group A receives a 4-month conservative management with sleep hygiene related adjustments, pelvic floor muscle training, and urologic health promotion. The intervention group B receives a 4-month conservative management with brief behavioral treatment for insomnia (BBTI), pelvic floor muscle training, and urologic health promotion. The comparison group receives information related to pelvic floor muscle training and urologic health promotion, and receives a brief conservative management related to sleep hygiene adjustments after the completion of data collection. Information related to intervention effects is obtained by a questionnaire, a wristwatch-like actigraphy, and physical activity/diet/voiding/sleep logs from all participants at 4 data collection points: baseline, and 2-, 4-, 6-month follow-ups. Our study hypothesis is that the intervention effects on relieving storage lower urinary tract symptoms and poor sleep, and on improving urologic health self-management behaviors and health-related quality of life in the intervention group A or B are superior to the changes revealed in the comparison group.

The goal of this clinical trial is to learn about the effect of the GMRx4 polypill compared to metformin monotherapy on glycosylated haemoglobin (HbA1c) when used as first line therapy in adults with recently diagnosed Type 2 Diabetes. The main question it aims to answer is: That the GMRx4 polypill, compared to metformin, will improve glucose lowering in those with recently diagnosed Type 2 Diabetes. Participants will be required to take either: One capsule of the GMRx4 polypill each morning and one 175mg metformin capsule each evening for 16 weeks. Or One metformin 500mg capsule each morning and each evening for 16 weeks. Participants will not know which of the two treatment regimens they will be taking. Participants will be provided with the necessary guidance information, equipment, online support and telephone/video calls from trained members of the study team to complete the study procedures at home although some support from a Healthcare Professional either at home or at a clinic will be offered if needed. The study will involve participants completing the following information and procedures and reporting electronically: Medical History (conditions and treatments) Gender Age Ethnicity/Race Weight Height Blood Pressure Heart Rate Blood collection for measurement of HbA1c (average blood glucose levels over a period of time), fasting glucose, creatinine and estimated glomerular filtration rate (eGFR) for kidney function, cholesterol, pregnancy (if not measured in a urine sample) Urine pregnancy test in women of child-bearing potential Concomitant Medications taken Safety outcomes Tolerability to the study treatment Adherence with taking the study treatment The number of any unused study treatment capsules

The peri-endoscopy management of diabetes mellitus creates significant challenges for both patients and healthcare professionals. These procedures require fasting and in certain situations, such as prior to a colonoscopy, the diet must be modified the day before the intervention and patients need to take a laxative. These factors put patients at high risk for hyperglycemia and hypoglycemia. Inadequate diabetes control or the continuation of certain medications during this period can be dangerous for the patient and lead to the cancellation of the procedure. DIAPI is a web application designed to generate orders for optimal and personalized treatment based on each patient's antidiabetic treatment, their glycemic control, their risk of hypoglycemia, and the intervention-related variables. DIAPI's algorithm is established on current evidence-based data when available, and experts' opinions. Information generated by DIAPI: For the patient: Clear instructions regarding their diabetes medication management for the days preceding and the day of the endoscopy. For the health care team: Clear instructions regarding patient's diabetes medication management for the days preceding and the day of the endoscopy; Individualized hyperglycemia protocol; Hypoglycemia protocol; Guidelines if SGLT2 inhibitors have not been discontinued pre-intervention; Suggestion on whether an Endocrinology consultation is needed. DIAPI aims to simplify the complex task of peri-intervention diabetes management while ensuring patient safety. It is a cost-effective solution that can lead to a reduction of unnecessary Endocrinology consultations, a decrease in nurses' workload, a lessening of the risk of errors and a diminution of endoscopy cancellation. The validation study is divided into two main phases. Phase 1 - Concordance. The investigators will assess the reproducibility of DIAPI orders when two different healthcare workers (an endocrinologist and a nurse) collect data for the same patient. The investigators hypothesize that DIAPI orders are concordant in 80%. Patients in this phase will be subjected to the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's. This group will be the control arm for the non-inferiority study (Phase 2). Phase 2 - Non-inferiority study. The investigators hypothesize that DIAPI's orders are not inferior to the recommendations issued by the treating-physician in terms of efficacy and security. Patients in this phase will be subjected DIAPI's orders. This group will be the intervention arm for the non-inferiority study.

Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease (NAFLD).This prospective study was designed to reveal the potential clinical application and underlying mechanisms of canagliflozin in the treatment of type 2 diabetes combined with nonalcoholic fatty liver disease.

More than 100 million U.S. adults are now living with diabetes or prediabetes. Investigators still do not fully understand how diabetes develops and how the disease worsens. Insulin is a hormone that helps the body use sugar as a fuel and control blood-sugar levels. People with diabetes have problems making insulin. This is because their insulin-producing beta cells -in the pancreas-are damaged or destroyed. A biomarker is a biological molecule (such as DNA, RNA (the genetic material of cells) or protein) that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker can be measured and found in blood and/or other body fluids (such as saliva and urine). Understanding the biology of beta cells could help find diabetes-related biomarkers. The discoveries from this research could help with early diagnosis of diabetes and lead to the creation of therapies for treating diabetes.